Advertisement
Screener

KYNTRA BIO, INC. (KYNB) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

1.8 / 5 stars · 34/94 Roast Me

KYNTRA BIO, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

KYNTRA BIO, INC. (KYNB) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $15.30 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09

  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $15.30M, a 34.64% decline year-over-year.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $20.00M.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $9.54M, a 11.14% increase year-over-year.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $16.92M, a 708.41% increase year-over-year.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $69.87M, a 955.06% increase from fiscal 2016.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $6.62M.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$5.87M.
  • KYNTRA BIO, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$107.29M, a 1095.44% decline from fiscal 2013.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filedNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2018-03-31$15.30M
10-Q · filed 2018-05-09
$35.30M
derived: sum of 2 quarters · filed 2018-05-09
$44.84M
derived: sum of 3 quarters · filed 2018-05-09
$61.76M
derived: sum of 4 quarters · filed 2018-05-09
2017-12-31$20.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
$29.54M
derived: sum of 2 quarters · filed 2018-02-27
$46.46M
derived: sum of 3 quarters · filed 2018-02-27
$69.87M
10-K · filed 2018-02-27
2017-09-30$9.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$26.46M
derived: sum of 2 quarters · filed 2017-11-08
$49.87M
10-Q · filed 2017-11-08
$40.75M
derived: sum of 4 quarters · filed 2018-05-09
2017-06-30$16.92M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$40.33M
10-Q · filed 2017-08-07
$31.21M
derived: sum of 3 quarters · filed 2018-05-09
$39.80M
derived: sum of 4 quarters · filed 2018-05-09
2017-03-31$23.41M
10-Q · filed 2018-05-09
$14.29M
derived: sum of 2 quarters · filed 2018-05-09
$22.88M
derived: sum of 3 quarters · filed 2018-05-09
$24.97M
derived: sum of 4 quarters · filed 2018-05-09
2016-12-31-$9.12M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
-$530.00K
derived: sum of 2 quarters · filed 2018-02-27
$1.56M
derived: sum of 3 quarters · filed 2018-02-27
$6.62M
10-K · filed 2018-02-27
2016-09-30$8.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08
$10.68M
derived: sum of 2 quarters · filed 2017-11-08
$15.74M
10-Q · filed 2017-11-08
$4.03M
derived: sum of 4 quarters · filed 2018-02-27
2016-06-30$2.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07
$7.15M
10-Q · filed 2017-08-07
-$4.55M
derived: sum of 3 quarters · filed 2018-02-27
-$4.76M
derived: sum of 4 quarters · filed 2018-02-27
2016-03-31$5.06M
10-Q · filed 2017-05-09
-$6.65M
derived: sum of 2 quarters · filed 2018-02-27
-$6.86M
derived: sum of 3 quarters · filed 2018-02-27
-$5.36M
derived: sum of 4 quarters · filed 2018-02-27
2015-12-31-$11.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27
-$11.91M
derived: sum of 2 quarters · filed 2018-02-27
-$10.42M
derived: sum of 3 quarters · filed 2018-02-27
-$5.87M
10-K · filed 2018-02-27
2015-09-30-$208.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-08
$1.29M
derived: sum of 2 quarters · filed 2016-11-08
$5.84M
10-Q · filed 2016-11-08
$14.30M
10-Q · filed 2015-11-12
-$134.46M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$1.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08
$6.05M
10-Q · filed 2016-08-08
-$134.25M
derived: sum of 3 quarters · filed 2017-03-01
-$130.84M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$4.55M
10-Q · filed 2016-05-09
-$135.74M
derived: sum of 2 quarters · filed 2017-03-01
-$132.33M
derived: sum of 3 quarters · filed 2017-03-01
-$114.95M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31-$140.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
-$136.88M
derived: sum of 2 quarters · filed 2017-03-01
-$119.50M
derived: sum of 3 quarters · filed 2017-03-01
-$107.29M
10-K · filed 2017-03-01
2014-09-30$3.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12
$20.79M
derived: sum of 2 quarters · filed 2015-11-12
$33.00M
10-Q · filed 2015-11-12
2014-06-30$17.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13
$29.59M
10-Q · filed 2015-08-13
2014-03-31$12.21M
10-Q · filed 2015-05-12
2013-12-31$10.78M
10-K · filed 2016-02-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
BeyondSpring Inc. (BYSI)United States$0.031B-10.95
AYTU BIOPHARMA, INC (AYTU)United States$0.025B-1.62
NANOVIRICIDES, INC. (NNVC)United States$0.031B
CHINA PHARMA HOLDINGS, INC. (CPHI)$0.032B
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
Propanc Biopharma, Inc. (PPCB)$0.032B-0.13